Literature DB >> 36018758

Arachidonate 5-lipoxygenase is essential for biosynthesis of specialized pro-resolving mediators and cardiac repair in heart failure.

Ganesh V Halade1, Vasundhara Kain1, Shahriare Hossain1, Vibhu Parcha2, Nita A Limdi3, Pankaj Arora2.   

Abstract

Arachidonate 5-lipoxygenase (ALOX5)-derived leukotrienes are primary signals of leukocyte activation and inflammation in response to ischemic cardiac injury (MI; myocardial infarction). Using risk-free male C57BL/6J and ALOX5-null mice (8-12 wk), we quantitated leukocytes and ALOX5-derived bioactive lipids of the infarcted left ventricle (LV) and spleen to measure the physiological inflammation and cardiac repair. Our results showed that ALOX5 endogenously generates specialized pro-resolving mediators (SPMs) that facilitate cardiac repair post-MI. Deficiency of ALOX5 leads to increase in cyclooxygenase gene expression, 6-keto prostaglandin F1α, and delayed neutrophil clearance with signs of unresolved inflammation post-MI. Consequently, ALOX5 deficiency impaired the resolution of inflammation and cardiac repair, including increased myocardium rupture post-MI in acute heart failure. On-time ALOX5 activation is critical for leukocyte clearance from the infarcted heart, indicating an essential role of ALOX5 in the resolution of inflammation. In addition, to balance the inflammatory responses, ALOX5 is also necessary for fibroblast signaling, as the ALOX5-deficient fibroblast are prone to fibroblast-to-myofibroblast differentiation leading to defective scar formation in post-MI cardiac repair. Consistent with these findings, ALOX5-null mice showed an overly inflammatory response, defective fibrotic signaling, and unresolved inflammation. These findings are indicative of a critical role of ALOX5 in myocardium healing, inflammation-resolution signaling, cardiac repair, and fibroblast pathophysiology.NEW & NOTEWORTHY Arachidonate 5-lipoxygenase (ALOX5) is critical in synthesizing specialized pro-resolving mediators that facilitate cardiac repair after cardiac injury. Thus, ALOX5 orchestrates the overlapping phases of inflammation and resolution to facilitate myocardium healing in cardiac repair postmyocardial infarction.

Entities:  

Keywords:  fibroblast signaling; inflammation; non-resolving inflammation; resolution of inflammation; specialized pro-resolving mediators

Mesh:

Substances:

Year:  2022        PMID: 36018758      PMCID: PMC9529265          DOI: 10.1152/ajpheart.00115.2022

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   5.125


  59 in total

1.  Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function.

Authors:  Vasundhara Kain; Kevin A Ingle; Romain A Colas; Jesmond Dalli; Sumanth D Prabhu; Charles N Serhan; Medha Joshi; Ganesh V Halade
Journal:  J Mol Cell Cardiol       Date:  2015-04-11       Impact factor: 5.000

Review 2.  Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.

Authors:  B Samuelsson; S E Dahlén; J A Lindgren; C A Rouzer; C N Serhan
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

Review 3.  Innate immunity and the failing heart: the cytokine hypothesis revisited.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

4.  Interaction of 12/15-lipoxygenase with fatty acids alters the leukocyte kinetics leading to improved postmyocardial infarction healing.

Authors:  Ganesh V Halade; Vasundhara Kain; Kevin A Ingle; Sumanth D Prabhu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-04-14       Impact factor: 4.733

Review 5.  Leukocyte diversity in resolving and nonresolving mechanisms of cardiac remodeling.

Authors:  Bochra Tourki; Ganesh Halade
Journal:  FASEB J       Date:  2017-06-22       Impact factor: 5.191

Review 6.  Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association.

Authors:  Eric B Rimm; Lawrence J Appel; Stephanie E Chiuve; Luc Djoussé; Mary B Engler; Penny M Kris-Etherton; Dariush Mozaffarian; David S Siscovick; Alice H Lichtenstein
Journal:  Circulation       Date:  2018-05-17       Impact factor: 29.690

7.  Urinary 11-Dehydro-Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study.

Authors:  Wojciech Szczeklik; Edyta Stodółkiewicz; Marcin Rzeszutko; Marek Tomala; Anton Chrustowicz; Krzysztof Żmudka; Marek Sanak
Journal:  J Am Heart Assoc       Date:  2016-08-01       Impact factor: 5.501

8.  Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction.

Authors:  Ganesh V Halade; Vasundhara Kain; Chrisly Dillion; Mark Beasley; Tanja Dudenbostel; Suzanne Oparil; Nita A Limdi
Journal:  ESC Heart Fail       Date:  2020-05-04

9.  Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction.

Authors:  Linn E Fosshaug; Romain A Colas; Anne K Anstensrud; Ida Gregersen; Ståle Nymo; Ellen L Sagen; Annika Michelsen; Leif E Vinge; Erik Øie; Lars Gullestad; Bente Halvorsen; Trond V Hansen; Pål Aukrust; Jesmond Dalli; Arne Yndestad
Journal:  EBioMedicine       Date:  2019-07-22       Impact factor: 8.143

10.  An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.

Authors:  Gabrielle Fredman; Jason Hellmann; Jonathan D Proto; George Kuriakose; Romain A Colas; Bernhard Dorweiler; E Sander Connolly; Robert Solomon; David M Jones; Eric J Heyer; Matthew Spite; Ira Tabas
Journal:  Nat Commun       Date:  2016-09-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.